Related Experiment Video
Updated: Sep 20, 2025
Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats
Published on: March 30, 2018
Allogenic perinatal tissue for musculoskeletal regenerative medicine applications: a systematic review protocol
Adarsh Aratikatla1, Nicola Maffulli2,3,4,5, Hugo C Rodriguez6,7
1The Royal College of Surgeons in Ireland, Dublin, Ireland.
Background:
Musculoskeletal ailments impact the lives of millions of people, and at times necessitate surgery followed by physiotherapy, drug treatments, or immobilization. Regenerative musculoskeletal medicine has undergone enormous progress over the last few decades. Sources of tissues used for regenerative medicine purposes can be grouped into autologous or allogenic. Although autologous sources are promising, there is a wide range of limitations with the treatment, including the lack of randomized controlled studies for orthopaedic conditions, donor site morbidity, and highly variable outcomes for patients. Allogenic sources bypass some of these shortcomings and are a promising source for orthopaedic regenerative medicine applications.
Methods:
A systematic search will be performed using PubMed, Elsevier, ScienceDirect, and Google Scholar databases for articles published in English before May 2022. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and guidelines will be used. Studies will be eligible if they apply to acute and chronic orthopaedic musculoskeletal complications or animal or human disease models. Publications must include the use of MSCs and/or tissue obtained from amniotic/chorionic membrane, amniotic fluid, umbilical cord, and/or umbilical cord-derived Wharton's jelly as an intervention. Placebos, noninjury models, acute injury models, non-injury models, and gold standard treatments will be compared. The study selection will be performed by two independent reviewers using a dedicated reference management software. Data synthesis and meta-analysis will be performed separately for preclinical and clinical studies.
Discussion:
The results will be published in relevant peer-reviewed scientific journals. Investigators will present results at national or international conferences.
Trial Registration:
The Protocol will be registered on PROSPERO international prospective register of systematic reviews prior to commencement.
